Medirom Healthcare Technologies Inc. Forms Alliance
Ticker: MRM · Form: 6-K · Filed: Aug 23, 2024 · CIK: 1819704
Sentiment: neutral
Topics: alliance, subsidiary, press-release
TL;DR
Medirom Healthcare subsidiary inks deal with NFES Technologies.
AI Summary
On August 23, 2024, Medirom Healthcare Technologies Inc. announced that its subsidiary, MEDIROM MOTHER Labs Inc., has entered into a capital and business alliance with NFES Technologies Inc. This filing is a Form 6-K report detailing this announcement.
Why It Matters
This alliance could lead to new service offerings or market expansion for Medirom Healthcare Technologies Inc. by leveraging the capabilities of NFES Technologies Inc.
Risk Assessment
Risk Level: low — The filing is an informational report about a business alliance and does not contain immediate financial risks.
Key Players & Entities
- Medirom Healthcare Technologies Inc. (company) — Registrant
- MEDIROM MOTHER Labs Inc. (company) — Subsidiary of Medirom Healthcare Technologies Inc.
- NFES Technologies Inc. (company) — Partner in capital and business alliance
- August 23, 2024 (date) — Date of press release and filing
FAQ
What is the nature of the capital and business alliance between MEDIROM MOTHER Labs Inc. and NFES Technologies Inc.?
The filing states that MEDIROM MOTHER Labs Inc. has entered into a capital and business alliance with NFES Technologies Inc., as announced in a press release dated August 23, 2024.
Which subsidiary of Medirom Healthcare Technologies Inc. is involved in this alliance?
MEDIROM MOTHER Labs Inc. is the subsidiary involved in the capital and business alliance.
What is the filing type and date?
This is a Form 6-K report filed on August 23, 2024.
Does this filing include an annual report?
No, the registrant indicates it files annual reports under Form 20-F, not this 6-K report.
What is the principal executive office address of Medirom Healthcare Technologies Inc.?
The principal executive office is located at 2-3-1 Daiba, Minato-ku, Tokyo 135-0091, Japan.
Filing Stats: 277 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-08-23 17:00:28
Filing Documents
- tmb-20240823x6k.htm (6-K) — 13KB
- tmb-20240823xex99d1.htm (EX-99.1) — 30KB
- tmb-20240823xex99d1001.jpg (GRAPHIC) — 4KB
- tmb-20240823xex99d1002.jpg (GRAPHIC) — 9KB
- tmb-20240823xex99d1003.jpg (GRAPHIC) — 4KB
- tmb-20240823xex99d1004.jpg (GRAPHIC) — 47KB
- tmb-20240823xex99d1005.jpg (GRAPHIC) — 8KB
- tmb-20240823xex99d1006.jpg (GRAPHIC) — 7KB
- tmb-20240823xex99d1007.jpg (GRAPHIC) — 7KB
- tmb-20240823xex99d1008.jpg (GRAPHIC) — 4KB
- 0001558370-24-012467.txt ( ) — 171KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MEDIROM HEALTHCARE TECHNOLOGIES INC. Date: August 23, 2024 By: /s/ Fumitoshi Fujiwara Name: Fumitoshi Fujiwara Title: Chief Financial Officer